ZARZIO (IP-NOVA) 30 mio U/0.5ml ser pré 5 pce
7680694050012
CH-69405
L03AA02
06.07.3.
Reimbursement limitations:
ZARZIO
Administration au cours des chimiothérapies fortement myélotoxiques permettant d'espérer une évolution positive chez les patients …
1 / 3
google
Details
- Product number
- 6940501
- CPT
- -
- Packaging group
- 5
- Unit
- Fertigspritze(n)
- Composition
- filgrastimum 0.30 mg corresp. filgrastimum 30 Mio. U., q.s. ad solutionem pro 0.5 ml.
Articles (1)
Zarzio 30 MU/0,5 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
5
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
0.3 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | Wirkstoff (Principe actif) |
Reimbursement information
Public price
CHF 290.20
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2024
Authorization holder
Pharma Nova GmbH
6340 Baar
Authorization information
- Swissmedic authorization number
- 69405
- Drug name
- Zarzio, Injektionslösung in einer Fertigspritze
- Galenic form
- INLFS
- ATC Code
- L03AA02
- Authorization status
- Z
- Authorization category
- Category P
- Dispensation category
- A
- First authorization
- 07/03/2024
- Authorization expiration date
- 06/03/2029
- IT number
- 06.07.3.
- Domain
- Human medicine
Packaging details
- Description (FR)
- ZARZIO (IP-NOVA) 30 mio U/0.5ml ser pré 5 pce
- Description (DE)
- ZARZIO (PI-NOVA) 30 Mio E/0.5ml Fertspr 5 Stk
- Market launch
- 07/03/2024
- Narcotic (BTM)
- No